Immunotherapy joins the fight against deadly prostate cancer
NCT ID NCT03543189
Summary
This study is testing whether adding an immunotherapy drug called nivolumab (Opdivo) to standard radiation and hormone therapy is safe and can help men with a very aggressive form of prostate cancer. The goal is to see if this combination can better control the cancer and prevent it from coming back. The trial is for men newly diagnosed with high-grade prostate cancer who are eligible for curative-intent radiation treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.